OSCOTECInc. Value-up Plan 2025 Progress Report: R&D Spending KRW 15.89 Billion
AI summary · Not investment advice
Oscotec filed its 2025 corporate value-up plan progress report, including R&D spending of KRW 15.89 billion, and is not a high-dividend company.
Key facts
- Key targets
- R&D investment (target: at least KRW 21.0 billion standalone by 2027) - KRW 15.89 billion in 2025 (up 66.4% year over year)R&D investment target and 2025 progress
- Key targets
- License-out (target: at least 5 deals by 2034) - 2 achieved: Sanofi (Dec 2025), Agios (Jun 2026)License-out target and progress
- Key targets
- New clinical trial (target: at least 1 by 2027) - OCT-598 Phase 1 started in Dec 2025 (achieved 2 years early)New clinical trial target and progress
- Key targets
- Profitability improvement (target: positive ROE by 2027) - 2025 consolidated revenue KRW 99.8 billion, operating profit KRW 52.1 billion, consolidated ROE 34.1% (achieved 2 years early)Profitability target and progress
- High-dividend company
- Not applicable
- Plan title
- Oscotec Corporate Value-up Plan Implementation Status (2025)
- PBR improvement plan
- Not included
- Tech-growth company plan
- Not included
- Decision date
- Nov 2, 2026Board report date
- Related materials
- https://oscotec.com/ko/investors/ir-materialPosted on 2026-11-04
Commentary
AI commentary · Not investment advice
What happened
Oscotec filed a progress report on its corporate value-up plan for 2025. The plan has 4 goals: R&D spending, license-out deals, new clinical trials and profitability.
In the company's terms
R&D spending was KRW 158.9 billion in 2025, up 66.4% from the prior year. The goal is at least KRW 21.0 billion on a standalone basis by 2027. For license-out deals (selling rights to its technology), the goal is 5 or more by 2034. 2 are done so far: Sanofi (December 2025) and Agios (June 2026).
What changes for shareholders
The goal for new clinical trials was at least 1 by 2027. The OCT-598 Phase 1 trial started in December 2025, 2 years early. For profitability, the goal was a positive return on equity (ROE, profit relative to shareholders' capital) by 2027. Consolidated 2025 revenue was KRW 99.8 billion and operating profit was KRW 52.1 billion. Consolidated ROE was 34.1%, also 2 years early.
The plan has no price-to-book ratio (PBR) improvement plan and no technology growth company plan. The company is not a high-dividend company. Details are on the company's investor relations page.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
O